Blue Jet Healthcare Reports Strong Q2 FY27 Results Driven by API Intermediates
Blue Jet Healthcare Ltd · Investor Presentation · 05 Nov 2026, 9:34 pm
Blue Jet Healthcare Reports Strong Q2 FY27 Results Driven by API Intermediates Blue Jet Healthcare reported revenue from operations of ₹3,757mn in Q2 ended 30th Sep'26, up 127.1% YoY and 28.2% QoQ, driven by a 322% YoY surge in Pharma Intermediates & APIs and an 80% increase in Contrast Media. EBITDA rose 116.1% YoY to ₹1,188mn (31.6% margin), while PAT climbed 96.6% YoY to ₹1,025mn (27.3% margin). For H1 FY27, revenue reached ₹6,689mn (+28.6% YoY) with PAT of ₹1,808mn. Additionally, its Hyderabad R&D facility became operational, with peptide fragment commercialization slated for Q4 FY27.
Original exchange filing (PDF)
More announcements from Blue Jet Healthcare Ltd
- Disclosure regarding the Signing of Memorandum of Understanding · 13 Nov 2026
- Transcript of Earnings call with analysts/Investors on Financial Result for the Quarter and Half Yearly ended 30th September, 2026. · 12 Nov 2026
- Submission of Audio recording of earnings conference call pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 · 06 Nov 2026
- Monitoring Agency Report for Quarter Ended September 30, 2026. · 05 Nov 2026
- Financials results for quarter and half year ended September 30, 2026. · 05 Nov 2026
- Blue Jet Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Outcome of Board Meeting held today i.e, Thursday, November 5, 2026. · 05 Nov 2026
- Intimation of Analyst and Investor call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 scheduled to be held on 5th November, 2026 · 05 Nov 2026
